.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02A_Antacids.A02AC01_CalciumCarbonate.CalciumCarbonate .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02A_Antacids.A02AC01_CalciumCarbonate.CalciumCarbonate| name: | CalciumCarbonate |
| ATC code: | A02AC01 | route: | oral |
| n-compartments | 1 |
Calcium carbonate is an inorganic compound commonly used as a dietary calcium supplement or antacid. It is approved for use in the treatment and prevention of calcium deficiency, osteoporosis, and as an adjunct therapy for conditions that benefit from increased calcium intake. It is widely available over the counter and is considered safe when used as directed.
Estimated pharmacokinetic parameters for healthy adult individuals from secondary sources; limited clinical PK studies due to its poor systemic absorption.
Junkert, AM, et al., & Pontarolo, R (2024). Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review. British journal of clinical pharmacology 90(2) 528–547. DOI:10.1111/bcp.15933 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37850318
Wiria, M, et al., & Pouteau, E (2020). Relative bioavailability and pharmacokinetic comparison of calcium glucoheptonate with calcium carbonate. Pharmacology research & perspectives 8(2) e00589–None. DOI:10.1002/prp2.589 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32302064
Pai, MP, et al., & Amsden, GW (2006). Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 5(3) 153–157. DOI:10.1016/j.jcf.2006.01.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16481224